US Capitol Capsule: Stage Set For More Federal Circuit Biosimilars Interpretive Dancing
This article was originally published in Scrip
Executive Summary
With an appeal filed last week by Apotex Inc. in a lawsuit brought against it by Amgen Inc. it looks like the US Court of Appeals for the Federal Circuit will have another chance to do some more interpretive dancing of the 2010 law that gave the FDA the authority to approve biosimilars – the Biologics Price Competition and Innovation Act (BPCIA).